Data Year:

For its 2024 fiscal year, C4 THERAPEUTICS INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Andrew J. Hirsch
President & Chief Executive Officer
Total Compensation $5,239,784 View details Pay Rank By Title In Biotechnology industry #255 View more
Leonard Reyno M.D.
Chief Medical Officer
Total Compensation $2,314,100 View details Pay Rank By Title In Biotechnology industry #156 View more
Kendra R. Adams
Chief Financial Officer
Total Compensation $2,197,489 View details Pay Rank By Title In Biotechnology industry #220 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at C4 THERAPEUTICS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. C4 THERAPEUTICS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. C4 THERAPEUTICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Andrew J. Hirsch
President & Chief Executive Officer
Total Cash $1,067,325 Equity $4,158,659 Other $13,800 $5,239,784
Leonard Reyno M.D.
Chief Medical Officer
Total Cash $823,680 Equity $1,476,620 Other $13,800 $2,314,100
Kendra R. Adams
Chief Financial Officer
Total Cash $698,400 Equity $1,486,274 Other $12,815 $2,197,489
For its 2024 fiscal year, C4 THERAPEUTICS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Bruce Downey Total Cash $201,188
Donna Grogan, M.D. Total Cash $186,625
Glenn Dubin Total Cash $18,300
Kenneth C. Anderson, M.D. Total Cash $176,625
Laura Bessen, M.D. Total Cash $180,625
Malcolm Salter Total Cash $36,538
Owen P. Hughes, Jr. Total Cash $179,125
Ronald Harold Wilfred Cooper Total Cash $346,199
Stephen Fawell, Ph.D. Total Cash $433,325
Stephen Hoerter Total Cash $274,417
Utpal Koppikar Total Cash $191,625
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.